Beth Marsh appointed as new Neurotech chief commercial officer

Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of revakinagene taroretcel-lwey (ENCELTO), approved for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

“I am confident that [Marsh’s] expertise in launching new therapies that address unmet needs, and her extensive network of leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch,” said Richard Small, chief executive officer for Neurotech.

Marsh comes to Neurotech with more than two decades of leadership and expertise in ophthalmology and retina. Most recently as Apellis Pharmaceuticals’ vice president, North America sales and marketing in ophthalmology, she led the company’s US commercial launch of pegcetacoplan (SYFOVRE) for the treatment of geographic atrophy secondary to age-related macular degeneration.

Related reading: A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

Marsh also served as the global product strategy lead of ophthalmology at Shire / Takeda Pharmaceuticals; and in her early career, served in commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. Other recognitions of Marsh include volunteer and past president of Ophthalmic World Leaders (OWL): Advancing diversity in leadership in ophthalmology.

“This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,” Marsh said.

The US Food and Drug Administration (FDA) approved revakinagene taroretcel-lwey (ENCELTO) in March. At the date of approval, revakinagene taroretcel-lwey is the first and only FDA-approved treatment for MacTel, utilizing an encapsulated cell therapy (ECT) technology designed to continually deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina, assisting in slowing the progression of the disease.

Related reading: Waiting on a treatment: How the history of MacTel is leading us into the future

Reference:

1. Neurotech Appoints Beth Marsh as Chief Commercial Officer.; 2025. Accessed April 21, 2025. https://www.neurotechpharmaceuticals.com/wp-content/uploads/Neurotech_Press-Release_Chief-Commercial-Officer_FINAL.pdf

2. Harp MD, Hayes H. FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2. Modern Retina. Published March 6, 2025. Accessed April 21, 2025. https://www.modernretina.com/view/fda-approves-revakinagene-taroretcel-lwey-encelto-for-macular-telangiectasia-type-2